# ANAVEX2-73 for Treatment of Early Alzheimer's Disease

> **NCT03790709** · PHASE2,PHASE3 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 509 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** High dose ANAVEX2-73
- **DRUG:** Mid dose ANAVEX2-73
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03790709
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-03
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790709, "ANAVEX2-73 for Treatment of Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03790709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*